InMed Pharmaceuticals (INM) Receivables - Net (2020 - 2025)
InMed Pharmaceuticals (INM) posted quarterly Receivables - Net of $182967.0 for Q4 2025, down 30.32% year-over-year from $262569.0 in Q4 2024, and down 46.73% quarter-over-quarter from $343469.0 in Q3 2025.
InMed Pharmaceuticals (INM) Receivables - Net (2020 - 2025) Analysis & Trends
InMed Pharmaceuticals' Receivables - Net history runs 6 years deep, the most recent figure standing at $182967.0 for Q4 2025.
- In Q4 2025, Receivables - Net fell 30.32% year-over-year to $182967.0; the TTM figure through Dec 2025 stood at $182967.0 (down 30.32% YoY), while the FY2025 annual figure was $2.0 million, up 5526.41% from the prior year.
- Receivables - Net for Q4 2025 stood at $182967.0, down from $343469.0 in the prior quarter.
- The five-year high for Receivables - Net was $465104.0 in Q2 2025, with the low at $11919.0 in Q2 2021.
- The 5-year median for Receivables - Net is $76100.5 (2022), against an average of $158022.6.
- The sharpest annual moves came in 2021 and 2025: Receivables - Net slumped 73.71% in 2021, then jumped 1240.36% in 2025.
- InMed Pharmaceuticals' Receivables - Net stood at $50304.0 in 2021, then soared by 62.31% to $81647.0 in 2022, then surged by 356.69% to $372870.0 in 2023, then slipped by 29.58% to $262569.0 in 2024, then plunged by 30.32% to $182967.0 in 2025.
- Business Quant data shows INM's Receivables - Net at $182967.0 in Q4 2025, $343469.0 in Q3 2025, and $465104.0 in Q2 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.94 Bn | 42.97 Bn | - |
| 2 | Teva Pharmaceutical Industries | 42.95 Bn | 39.30 Bn | 2.15 Bn |
| 3 | Zoetis | 31.58 Bn | 29.90 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.16 Bn | 19.49 Bn | 683.80 Mn |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.53 Bn | 15.14 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.76 Bn | 11.23 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.95 Bn | - |
| 10 | InMed Pharmaceuticals | 6.44 Mn | 1.20 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 182,967.00 |
| Dec 31, 2025 | 182,967.00 |
| Sep 30, 2025 | 343,469.00 |
| Sep 30, 2025 | 343,469.00 |
| Jun 30, 2025 | 465,104.00 |
| Jun 30, 2025 | 465,104.00 |
| Mar 31, 2025 | 367,813.00 |
| Mar 31, 2025 | 367,813.00 |
| Dec 31, 2024 | 262,569.00 |
| Dec 31, 2024 | 262,569.00 |
| Sep 30, 2024 | 284,695.00 |
| Sep 30, 2024 | 284,695.00 |
| Jun 30, 2024 | 34,700.00 |
| Jun 30, 2024 | 34,700.00 |
| Mar 31, 2024 | 207,681.00 |
| Mar 31, 2024 | 207,681.00 |
| Dec 31, 2023 | 372,870.00 |
| Dec 31, 2023 | 372,870.00 |
| Sep 30, 2023 | 66,775.00 |
| Sep 30, 2023 | 66,775.00 |